Alpine Immune Sciences (ALPN) News Today → Urgent Nvidia Warning (From Altimetry) (Ad) Free ALPN Stock Alerts $64.97 +0.01 (+0.02%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 6:00 AM | marketbeat.comJump Financial LLC Buys Shares of 55,720 Alpine Immune Sciences, Inc. (NASDAQ:ALPN)Jump Financial LLC bought a new position in Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 55,720 shares of the biotechnology company's stock, valued at approximately $1,062,00May 18 at 5:02 AM | americanbankingnews.comAlpine Immune Sciences (NASDAQ:ALPN) Stock Rating Reaffirmed by WedbushMay 16 at 10:54 AM | markets.businessinsider.comWhat 11 Analyst Ratings Have To Say About Alpine Immune SciencesMay 16 at 9:50 AM | marketbeat.comAlpine Immune Sciences (NASDAQ:ALPN) Given "Neutral" Rating at WedbushWedbush reissued a "neutral" rating and set a $65.00 price objective on shares of Alpine Immune Sciences in a report on Thursday.May 16 at 1:34 AM | americanbankingnews.comAlpine Immune Sciences, Inc. (NASDAQ:ALPN) Receives Average Recommendation of "Hold" from AnalystsMay 16 at 1:32 AM | marketbeat.comAlpine Immune Sciences, Inc. (NASDAQ:ALPN) Receives Consensus Recommendation of "Hold" from AnalystsShares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Get Free Report) have received a consensus rating of "Hold" from the eleven analysts that are covering the stock, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a hold recommendation and three have assigned a buMay 14, 2024 | marketbeat.comAlpine Immune Sciences (NASDAQ:ALPN) Reaches New 52-Week High at $64.96Alpine Immune Sciences (NASDAQ:ALPN) Hits New 12-Month High at $64.96May 13, 2024 | marketbeat.comAlpine Immune Sciences, Inc. (NASDAQ:ALPN) Sees Significant Drop in Short InterestAlpine Immune Sciences, Inc. (NASDAQ:ALPN - Get Free Report) saw a significant decline in short interest in April. As of April 30th, there was short interest totalling 3,890,000 shares, a decline of 17.9% from the April 15th total of 4,740,000 shares. Based on an average daily trading volume, of 2,230,000 shares, the short-interest ratio is currently 1.7 days.May 12, 2024 | americanbankingnews.comAlpine Immune Sciences (NASDAQ:ALPN) Sees Strong Trading VolumeMay 10, 2024 | marketbeat.comAlpine Immune Sciences (NASDAQ:ALPN) Sees Large Volume IncreaseAlpine Immune Sciences (NASDAQ:ALPN) Sees Large Volume IncreaseMay 10, 2024 | investorplace.comALPN Stock Earnings: Alpine Immune Sciences Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | businesswire.comAlpine Immune Sciences Reports First Quarter 2024 Financial ResultsMay 9, 2024 | marketbeat.comAlpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares Sold by Vivo Capital LLCVivo Capital LLC lowered its holdings in Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Free Report) by 10.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 819,275 shares of the biotechnology company's stock afterMay 8, 2024 | marketbeat.comAlpine Immune Sciences (NASDAQ:ALPN) Sets New 52-Week High at $64.72Alpine Immune Sciences (NASDAQ:ALPN) Sets New 12-Month High at $64.72May 7, 2024 | finance.yahoo.comVertex Pharmaceuticals Inc (VRTX) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ...May 1, 2024 | morningstar.comAlpine Immune Sciences IncApril 29, 2024 | marketbeat.comAlpine Immune Sciences (NASDAQ:ALPN) Sets New 1-Year High at $64.70Alpine Immune Sciences (NASDAQ:ALPN) Sets New 12-Month High at $64.70April 27, 2024 | marketbeat.comVivo Capital LLC Sells 298,770 Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN)Vivo Capital LLC lessened its stake in Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Free Report) by 36.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 520,505 shares of the biotechnology company's stock after selling 298,770 shares duriApril 27, 2024 | benzinga.comLatest News for Alpine Immune Sciences Stock (NASDAQ:ALPN)April 27, 2024 | businesswire.comALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune ...April 26, 2024 | businesswire.comALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPNApril 23, 2024 | finance.yahoo.comAlpine Immune Sciences, Inc. (ALPN)April 22, 2024 | marketbeat.comAlpine Immune Sciences (NASDAQ:ALPN) Sets New 1-Year High at $64.58Alpine Immune Sciences (NASDAQ:ALPN) Sets New 12-Month High at $64.58April 18, 2024 | msn.comTD Cowen Downgrades Alpine Immune Sciences (ALPN)April 17, 2024 | prnewswire.comINVESTIGATION: The M&A Class Action Firm Announces an Investigation of Alpine Immune Sciences, Inc. - ALPNApril 17, 2024 | msn.comAlpine Immune Sciences (ALPN) Price Target Increased by 36.91% to 63.24April 16, 2024 | marketbeat.comAlpine Immune Sciences (NASDAQ:ALPN) Given "Hold" Rating at TD CowenTD Cowen reaffirmed a "hold" rating on shares of Alpine Immune Sciences in a research note on Tuesday.April 15, 2024 | investorplace.comCan You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?April 15, 2024 | marketbeat.comAlpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares Bought by Vanguard Group Inc.Vanguard Group Inc. increased its holdings in Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Free Report) by 5.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,474,879 shares of the biotechnology company's stock afterApril 13, 2024 | marketbeat.comAlpine Immune Sciences (NASDAQ:ALPN) Downgraded by Leerink Partnrs to Market PerformLeerink Partnrs cut Alpine Immune Sciences from an "outperform" rating to a "market perform" rating in a report on Thursday.April 13, 2024 | fool.comCould This Stock Be the Next Biotech Buyout?April 12, 2024 | stockhouse.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Alpine Immune Sciences, Inc. BuyoutApril 12, 2024 | businesswire.comALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPNApril 12, 2024 | marketbeat.comAlpine Immune Sciences' (ALPN) "Market Perform" Rating Reaffirmed at SVB LeerinkSVB Leerink reissued a "market perform" rating and set a $65.00 price target (up previously from $42.00) on shares of Alpine Immune Sciences in a research report on Friday.April 12, 2024 | marketbeat.comAlpine Immune Sciences (NASDAQ:ALPN) Downgraded by HC WainwrightHC Wainwright downgraded Alpine Immune Sciences from a "buy" rating to a "neutral" rating in a report on Thursday.April 11, 2024 | finance.yahoo.comThese Stocks Moved the Most Today: CarMax, Apple, Fastenal, Rivian, Alpine Immune, Nike, Robinhood, Constellation Brands, and MoreApril 11, 2024 | seekingalpha.comVertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'April 11, 2024 | barrons.comVertex Pharmaceuticals to Buy Alpine Immune in $4.9B DealApril 11, 2024 | investors.comAlpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy ItApril 11, 2024 | investorplace.comThe $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% TodayApril 11, 2024 | marketbeat.comAlpine Immune Sciences' (ALPN) "Neutral" Rating Reaffirmed at WedbushWedbush reaffirmed a "neutral" rating on shares of Alpine Immune Sciences in a research report on Thursday.April 11, 2024 | proactiveinvestors.comAlpine Immune Sciences soars on $4.9bn Vertex takeoverApril 10, 2024 | investopedia.comVertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B—Key Level to WatchApril 10, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Alpine Immune Sciences, Inc. has obtained a Fair Price in its transaction with VertexApril 10, 2024 | businesswire.comALPN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alpine Immune Sciences, Inc. Is Fair to ShareholdersApril 10, 2024 | investors.comVertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion DealApril 10, 2024 | reuters.comVertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 blnApril 10, 2024 | marketbeat.comTrading was temporarily halted for "ALPN" at 04:04 PM with a stated reason of "News pending."April 10, 2024 | bloomberg.comAlpine Immune Is Weighing Options After Takeover InterestApril 10, 2024 | benzinga.comWhy Is Kidney Disease-Focused Alpine Immune Sciences Stock Trading Higher On Wednesday? Get Alpine Immune Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter. Email Address Obama’s Forever Term [exposed] (Ad)America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision. Start streaming it now at no cost here ALPN Media Mentions By Week ALPN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALPN News Sentiment▼1.260.42▲Average Medical News Sentiment ALPN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALPN Articles This Week▼93▲ALPN Articles Average Week Get Alpine Immune Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MDGL News NUVL News ALKS News PRGO News CRNX News INSM News HCM News APLS News AXSM News PBH News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALPN) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubNext President (Not Trump. Not Biden.)The Freeport SocietyCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alpine Immune Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
